We previously reported that ERK1/2 inhibition synergizes liver X receptor (LXR)-reduced atherosclerosis in apoE deficient (apoE-/-) mice by enhancing reverse cholesterol transport and ATP-binding cassette transporter A1 (ABCA1) expression 23. This evidence concerns the gene MAPK3 and atherosclerosis.